Iterum Therapeutics plc (ITRM)
NASDAQ: ITRM · IEX Real-Time Price · USD
1.570
+0.020 (1.29%)
At close: Apr 25, 2024, 3:59 PM
1.600
+0.030 (1.91%)
After-hours: Apr 25, 2024, 6:04 PM EDT

Iterum Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019201820172016
Cash & Equivalents
6.1121.1327.5114.574.8344.588.4924.81
Short-Term Investments
17.8639.7153.9004030.730
Cash & Cash Equivalents
23.9660.8481.4114.574.8384.5839.2224.81
Cash Growth
-60.61%-25.27%458.81%201.55%-94.29%115.68%58.07%-
Other Current Assets
1.631.611.866.96.898.394.961.05
Total Current Assets
25.662.4483.2721.4711.7292.9744.1725.86
Property, Plant & Equipment
0.050.070.090.420.570.70.750
Long-Term Investments
0000.250.060.0900
Goodwill and Intangibles
01.723.4400000
Other Long-Term Assets
0.612.64.7210.6513.44.111.841.06
Total Long-Term Assets
0.664.398.2411.3214.034.92.581.06
Total Assets
26.2666.8391.5132.7925.7597.8746.7626.92
Accounts Payable
52.770.880.8215.494.043.151.48
Current Debt
001.636.495.81.0200
Other Current Liabilities
8.526.2910.4434.3915.77.163.972.74
Total Current Liabilities
13.529.0612.9441.736.9912.227.134.22
Long-Term Debt
18.9628.4724.935.857.6313.0800
Other Long-Term Liabilities
0.191.33.445.87.380.950.080
Total Long-Term Liabilities
19.1429.7728.3341.651514.030.080
Total Liabilities
32.6638.8341.2883.3551.9926.257.214.22
Total Debt
18.9628.4726.5342.3413.4314.100
Debt Growth
-33.41%7.32%-37.35%215.37%-4.77%---
Retained Earnings
-461.3-422.93-378.49-286.93-234.92-131.79-54.74-25.33
Comprehensive Income
0-0.35000000
Shareholders' Equity
-6.42850.23-50.56-26.2471.6239.4922.67
Net Cash / Debt
5.0132.3754.88-27.77-8.5970.4839.2224.81
Net Cash / Debt Growth
-84.53%-41.02%---79.73%58.07%-
Net Cash Per Share
0.392.655.04-17.35-8.88121.053417.5215721.80
Working Capital
12.0853.3870.33-20.23-25.2780.7537.0521.64
Book Value Per Share
-0.492.294.61-31.59-27.11123.003441.6414366.23
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).